Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Up 42.8% in July

Assembly Biosciences, Inc. (NASDAQ:ASMBGet Rating) was the recipient of a significant increase in short interest in the month of July. As of July 15th, there was short interest totalling 1,290,000 shares, an increase of 42.8% from the June 30th total of 903,300 shares. Based on an average daily volume of 498,900 shares, the short-interest ratio is presently 2.6 days. Approximately 5.8% of the shares of the stock are short sold.

Assembly Biosciences Trading Down 2.9 %

NASDAQ:ASMB opened at $2.01 on Tuesday. The firm has a 50 day moving average of $2.06 and a 200-day moving average of $1.88. Assembly Biosciences has a 1 year low of $1.32 and a 1 year high of $3.94.

Assembly Biosciences (NASDAQ:ASMBGet Rating) last posted its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.01. On average, equities research analysts predict that Assembly Biosciences will post -1.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. StockNews.com upgraded shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, May 24th. HC Wainwright cut their target price on shares of Assembly Biosciences from $3.50 to $2.50 in a research note on Thursday, July 21st. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $7.90.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Deep Track Capital LP bought a new position in Assembly Biosciences in the 4th quarter worth approximately $6,990,000. Candriam Luxembourg S.C.A. grew its holdings in Assembly Biosciences by 25.1% during the 4th quarter. Candriam Luxembourg S.C.A. now owns 1,838,221 shares of the biopharmaceutical company’s stock worth $4,283,000 after acquiring an additional 369,375 shares during the period. Acadian Asset Management LLC grew its holdings in Assembly Biosciences by 13.9% during the 4th quarter. Acadian Asset Management LLC now owns 1,608,760 shares of the biopharmaceutical company’s stock worth $3,746,000 after acquiring an additional 196,033 shares during the period. Assenagon Asset Management S.A. grew its holdings in Assembly Biosciences by 1,422.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 684,846 shares of the biopharmaceutical company’s stock worth $1,438,000 after acquiring an additional 639,859 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in Assembly Biosciences by 54.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 553,428 shares of the biopharmaceutical company’s stock worth $1,289,000 after acquiring an additional 194,113 shares during the period. Institutional investors own 52.63% of the company’s stock.

About Assembly Biosciences

(Get Rating)

Assembly Biosciences, Inc, a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.

See Also

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.